British Journal of Renal Medicine - 2020


Invisible enemies
John Bradley
pp 3-3

In 1964 Baruch Blumberg recognised that individuals transfused with blood from another individual develop antibodies against the donor’s serum proteins when they differ slightly from their own. These ‘isoprecipitins’ could be identified by their ability to precipitate the protein or antigen. Most of these isoprecipitins reacted with serum lipoproteins, but an isoprecipitin was also identified that reacted with an as yet unidentified protein. This isoprecipitin was found in patients who had received multiple blood transfusions, and was commoner in certain populations including Australian aborigines (Blumberg, 1964).1

Reduction in intravascular catheterrelated infections in haemodialysis patients: a single centre experience
Shaista Tamizuddin
pp 4-8

Millions of people worldwide have end-stage kidney disease (ESKD) and need renal replacement therapy (RRT). According to the 21st annual report of the UK renal registry, there were 64,887 adult patients receiving RRT at the end of 2017, among which 39.7% were on hemodialysis (HD).

Sharing kidney stories: ‘Partnership working’ brought to life at a family involvement event
Cara Davis
pp 9-3

Having a chronic kidney disease (CKD) can have a considerable impact on the lives of children and young people (CYP) with the disease and those of their families.1–3 Impaired physical growth and difficulties of psychosocial adjustment can impair quality of life, with some CYP experiencing depression and adjustment disorders.4 Professionals working with CYP with CKD recognise these can report difficulties with low mood, anxiety, body image, friendships, schooling, loneliness, isolation, pain and fatigue, as well as existential thoughts of ‘Why me?’.

Galactorrhoea in end-stage renal disease
Hannah Hudson
pp 14-15

A 21-year-old male Caucasian patient presented as an emergency with end-stage renal disease (ESRD), with a creatinine concentration of 2,852 µmol/l, features of chronic nephritis with proteinuria (urine protein:creatinine ratio of 407.4 mg/mmol), and atrophic kidneys on ultrasonography. Investigations for Fabry disease (alpha-galactosidase A), HIV and hepatitis B/C infection and immune-mediated renal disease (antinuclear, antineutrophil cytoplasmic and anti-glomerular basement membrane antibodies) were all negative. The patient was commenced on renal replacement therapy (RRT), initially in the form of haemodialysis (HD) and subsequently switched to peritoneal dialysis (PD). As PD was unsuccessful because of inadequate dialysis, he was switched back on to HD and was evaluated for a living donor transplant. At initial presentation, he was commenced on the H2 receptor antagonist ranitidine, administered orally at a dose of 150 mg twice a day. This was prompted by concerns about his severe anaemia (haemoglobin <40 g/l) and high risk of peptic ulceration in the setting of an extreme uraemic emergency.

We know ourselves only as far as we’ve been tested
Donal J O’Donoghue
pp 16-17

People with kidney disease have been hugely affected by the pandemic. Those with kidney transplants and receiving immunosuppressive drugs to control their kidney disease were contacted and advised to self-isolate for at least 12 weeks at the start of the pandemic. They became part of the 2.2 million people in England who have been shielding over these past three months. It became apparent early on that, alongside other risk multipliers of age and being part of a BAME community, people receiving maintenance haemodialysis had a high risk of infection and mortality and, as such, were advised to shield, other than their necessary visits to the haemodialysis unit. In a number of units haemodialysis was reduced from three times per week to twice weekly for those patients able to tolerate this reduction. Control of potassium was made possible by the use of the newer potassium binding agents for these patients.

The challenges of assessing the incidence and severity of community acquired acute kidney injury among unselected emergency admissions in a rural district hospital in Sierra Leone
David Hamilton
pp 18-22

A cute kidney injury (AKI) is the loss of kidney function over a short period of time and manifests as a rise in serum creatinine levels from baseline and/or a fall in urine output. It is well established that AKI is associated with high rates of mortality and morbidity and it has been estimated that 1.7 million deaths worldwide are attributable to AKI annually. The burden of AKI disproportionally affects low- and middle-income countries (LMICs), where the resources are most scarce.

BK polyomavirus practice patterns in the UK – results from a 2018 survey of UK renal centres
Rhodri Pyart
pp 23-27

BK virus (BKV) reactivation following kidney transplantation is estimated to occur in up to 10% of recipients and can cause the development of an associated nephropathy. BKV nephropathy results in long-term allograft damage, a reduction in graft longevity and graft loss in 15–50% of those affected.1 Transplants may also be lost due to rejection, triggered by a reduction in immunosuppression aimed at preventing BKV replication. Risk factors for BKV nephropathy are not fully understood, but intensity of immunosuppression and certain donor and recipient characteristics are known to contribute to the risk.

The British Journal of Renal Medicine was previously supported by Baxter Healthcare from 2011 to 2013, by Sandoz in 2011, by Shire Pharmaceuticals from 2006 to 2011, by Ortho Biotech and Shire Pharmaceuticals in 2005, by Ortho Biotech from 2000 to 2005 and by Janssen Cilag from 1996 to 2000.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the sponsors, publisher, Editor or Editorial Board. Accordingly, the sponsors, publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.

The title British Journal of Renal Medicine is the property of Hayward Medical Publishing and PMGroup Worldwide Ltd and, together with the content, is bound by copyright. Copyright © 2019 PMGroup Worldwide Ltd. All rights reserved. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to: admin@hayward.co.uk

ISSN 1365-5604 (Print)  ISSN 2045-7839 (Online)